Literature DB >> 28719151

Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients.

Barnaby Nelson1,2, G Paul Amminger1,2, Hok Pan Yuen1,2, Nicky Wallis1,2, Melissa J Kerr1,2, Lisa Dixon3, Cameron Carter4, Rachel Loewy5, Tara A Niendam4, Martha Shumway5, Sarah Morris6, Julie Blasioli1,2, Patrick D McGorry1,2.   

Abstract

AIM: Previous research indicates that preventive intervention is likely to benefit patients "at risk" of psychosis, in terms of functional improvement, symptom reduction and delay or prevention of onset of threshold psychotic disorder. The primary aim of the current study is to test outcomes of ultra high risk (UHR) patients, primarily functional outcome, in response to a sequential intervention strategy consisting of support and problem solving (SPS), cognitive-behavioural case management and antidepressant medication. A secondary aim is to test biological and psychological variables that moderate and mediate response to this sequential treatment strategy.
METHODS: This is a sequential multiple assignment randomised trial (SMART) consisting of three steps: Step 1: SPS (1.5 months); Step 2: SPS vs Cognitive Behavioural Case Management (4.5 months); Step 3: Cognitive Behavioural Case Management + Antidepressant Medication vs Cognitive Behavioural Case Management + Placebo (6 months). The intervention is of 12 months duration in total and participants will be followed up at 18 months and 24 months post baseline.
CONCLUSION: This paper reports on the rationale and protocol of the Staged Treatment in Early Psychosis (STEP) study. With a large sample of 500 UHR participants this study will investigate the most effective type and sequence of treatments for improving functioning and reducing the risk of developing psychotic disorder in this clinical population.
© 2017 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  antidepressant medication; clinical trial; prodrome; psychosis; ultra high risk

Mesh:

Substances:

Year:  2017        PMID: 28719151      PMCID: PMC6054879          DOI: 10.1111/eip.12459

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  102 in total

1.  Preventing progression to first-episode psychosis in early initial prodromal states.

Authors:  A Bechdolf; M Wagner; S Ruhrmann; S Harrigan; V Putzfeld; R Pukrop; A Brockhaus-Dumke; J Berning; B Janssen; P Decker; R Bottlender; K Maurer; H-J Möller; W Gaebel; H Häfner; W Maier; J Klosterkötter
Journal:  Br J Psychiatry       Date:  2011-11-10       Impact factor: 9.319

2.  Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry.

Authors:  Patrick D McGorry
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

3.  Impaired context processing as a potential marker of psychosis risk state.

Authors:  Tara A Niendam; Tyler A Lesh; Jong Yoon; Andrew J Westphal; Natalie Hutchison; J Daniel Ragland; Marjorie Solomon; Michael Minzenberg; Cameron S Carter
Journal:  Psychiatry Res       Date:  2013-10-11       Impact factor: 3.222

4.  The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.

Authors:  V Sanchez; J Camarero; B Esteban; M J Peter; A R Green; M I Colado
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

5.  The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample.

Authors:  Elaine F Walker; Barbara A Cornblatt; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Scott W Woods; Robert Heinssen
Journal:  Schizophr Res       Date:  2009-08-25       Impact factor: 4.939

6.  Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals.

Authors:  Daqiang Sun; Lisa Phillips; Dennis Velakoulis; Alison Yung; Patrick D McGorry; Stephen J Wood; Theo G M van Erp; Paul M Thompson; Arthur W Toga; Tyrone D Cannon; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-12       Impact factor: 4.939

7.  Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial.

Authors:  Mette Bertelsen; Pia Jeppesen; Lone Petersen; Anne Thorup; Johan Øhlenschlaeger; Phuong le Quach; Torben Østergaard Christensen; Gertrud Krarup; Per Jørgensen; Merete Nordentoft
Journal:  Arch Gen Psychiatry       Date:  2008-07

8.  Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study.

Authors:  Barnaby Nelson; Hok Pan Yuen; Stephen J Wood; Ashleigh Lin; Daniela Spiliotacopoulos; Annie Bruxner; Christina Broussard; Magenta Simmons; Debra L Foley; Warrick J Brewer; Shona M Francey; G Paul Amminger; Andrew Thompson; Patrick D McGorry; Alison R Yung
Journal:  JAMA Psychiatry       Date:  2013-08       Impact factor: 21.596

9.  Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress.

Authors:  Olivier Berton; Colleen A McClung; Ralph J Dileone; Vaishnav Krishnan; William Renthal; Scott J Russo; Danielle Graham; Nadia M Tsankova; Carlos A Bolanos; Maribel Rios; Lisa M Monteggia; David W Self; Eric J Nestler
Journal:  Science       Date:  2006-02-10       Impact factor: 47.728

10.  Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia.

Authors:  Barbara A Cornblatt; Andrea M Auther; Tara Niendam; Christopher W Smith; Jamie Zinberg; Carrie E Bearden; Tyrone D Cannon
Journal:  Schizophr Bull       Date:  2007-04-17       Impact factor: 9.306

View more
  14 in total

1.  Beyond the "at risk mental state" concept: transitioning to transdiagnostic psychiatry.

Authors:  Patrick D McGorry; Jessica A Hartmann; Rachael Spooner; Barnaby Nelson
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  Integrating Genomics into Psychiatric Practice: Ethical and Legal Challenges for Clinicians.

Authors:  Eric T Ward; Kristin M Kostick; Gabriel Lázaro-Muñoz
Journal:  Harv Rev Psychiatry       Date:  2019 Jan/Feb       Impact factor: 3.732

3.  The Global Functioning: Social and Role Scales-Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis.

Authors:  Ricardo E Carrión; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Barbara A Cornblatt
Journal:  Schizophr Bull       Date:  2019-06-18       Impact factor: 9.306

4.  Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains.

Authors:  Dana M Allswede; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Daniel H Mathalon; Thomas McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Tyrone D Cannon
Journal:  Am J Psychiatry       Date:  2019-09-06       Impact factor: 18.112

5.  Multidisciplinary Treatment for Individuals at Clinical High Risk of Developing Psychosis.

Authors:  Jean Addington; Daniel J Devoe; Olga Santesteban-Echarri
Journal:  Curr Treat Options Psychiatry       Date:  2019-01-31

6.  Psychological interventions for psychosis in adolescents.

Authors:  Soumitra S Datta; Rhea Daruvala; Ajit Kumar
Journal:  Cochrane Database Syst Rev       Date:  2020-07-03

7.  NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical course.

Authors:  B Nelson; G P Amminger; H P Yuen; C Markulev; S Lavoie; M R Schäfer; J A Hartmann; N Mossaheb; M Schlögelhofer; S Smesny; I B Hickie; G Berger; E Y H Chen; L de Haan; D H Nieman; M Nordentoft; A Riecher-Rössler; S Verma; A Thompson; A R Yung; P D McGorry
Journal:  NPJ Schizophr       Date:  2018-06-25

Review 8.  Functional deficits in attenuated psychosis syndrome and related conditions: Current and future treatment options.

Authors:  Philip D Harvey; Mackenzie Taylor Jones
Journal:  Schizophr Res Cogn       Date:  2019-05-15

9.  Recent Meta-Analyses in the Clinical High Risk for Psychosis Population: Clinical Interpretation of Findings and Suggestions for Future Research.

Authors:  Barnaby Nelson; Günter Paul Amminger; Patrick Denistoon McGorry
Journal:  Front Psychiatry       Date:  2018-10-12       Impact factor: 4.157

10.  What Would Digital Early Intervention for Bipolar Disorder Look Like? Theoretical and Translational Considerations for Future Therapies.

Authors:  Greg Murray
Journal:  Front Psychiatry       Date:  2019-08-23       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.